menu
    • menu
    [{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Apollo Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"ES Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"AVTX-007","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ ES Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ ES Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camoteskimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ AUG Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ AUG Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Immunology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Fucose","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avalo Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Avalo Therapeutics

    Menu

    Avalo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVTX-009

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Commodore Capital

                            Deal Size : $69.4 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Avalo Secures $69.4M From Full Exercise of Private Placement Warrants

                            Details : The proceeds will be used to advance AVTX-009, an anti-IL-1β antibody targeting inflammatory diseases, in development for the treatment of hidradenitis suppurativa.

                            Product Name : AVTX-009

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : AVTX-009

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Commodore Capital

                            Deal Size : $69.4 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVTX-009

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avalo Therapeutics Gets Active IND for AVTX-009 in Hidradenitis Suppurativa

                            Details : AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1 beta, being developed for moderate to severe hidradenitis suppurativa.

                            Product Name : AVTX-009

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : AVTX-009

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVTX-009

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avalo Doses First Patient in AVTX-009 Phase 2 LOTUS Trial For Hidradenitis

                            Details : AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1 beta, being developed for moderate to severe hidradenitis suppurativa.

                            Product Name : AVTX-009

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 10, 2024

                            Lead Product(s) : AVTX-009

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alpha-D-Galactose

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : AUG Therapeutics

                            Deal Size : $45.1 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Avalo Enters into Agreement to Divest AVTX-800 Series

                            Details : Under the divestiture, AUG gains rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose). AVTX-801 is a therapeutic dose of D-galactose currently in development for the treatment of phosphogl...

                            Product Name : AVTX-801

                            Product Type : Other Small Molecule

                            Upfront Cash : $0.1 million

                            December 09, 2023

                            Lead Product(s) : Alpha-D-Galactose

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : AUG Therapeutics

                            Deal Size : $45.1 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinoph...

                            Details : AVTX-002 (quisovalimab) is a fully human monoclonal antibody (mAb), directed against human LIGHT, and investigated for the treatment of patients with poorly controlled non-eosinophilic asthma

                            Product Name : AVTX-002

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 26, 2023

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : SVB Securities

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

                            Details : AVTX-002 is a fully human monoclonal antibody, directed against human LIGHT. AVTX-002 is currently in Phase 2 development for non-eosinophilic asthma (NEA) with proof-of-concept data in inflammatory bowel diseases (IBD) and COVID-19 acute respiratory dis...

                            Product Name : AVTX-002

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 02, 2023

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : SVB Securities

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-E...

                            Details : AVTX-002 is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes...

                            Product Name : AVTX-002

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVTX-007

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : ES Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

                            Details : AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA).

                            Product Name : AVTX-007

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 11, 2022

                            Lead Product(s) : AVTX-007

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : ES Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presen...

                            Details : AVTX-002 (MDGN-002) Phase 1b CD clinical trial result demonstrated clinically meaningful mucosal healing in 75% of patients. Data continued to show that treatment with AVTX-002 was safe and well-tolerated with no drug-related serious adverse events obser...

                            Product Name : AVTX-002

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : Quisovalimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Avalo Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camoteskimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of No...

                            Details : MDGN-002 (AVTX-002) is a fully human anti-LIGHT, monoclonal antibody in development for the treatment of acute respiratory distress syndrome (ARDS), the treatment of inflammatory bowel disease (IBD) and the treatment of non-eosinophilic asthma.

                            Product Name : MDGN-002

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : Camoteskimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth